0001127602-13-003944.txt : 20130204
0001127602-13-003944.hdr.sgml : 20130204
20130204165659
ACCESSION NUMBER: 0001127602-13-003944
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20130131
FILED AS OF DATE: 20130204
DATE AS OF CHANGE: 20130204
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tessmer James F
CENTRAL INDEX KEY: 0001434095
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30111
FILM NUMBER: 13570754
MAIL ADDRESS:
STREET 1: 8800 TECHNOLOGY FOREST PLACE
CITY: THE WOODLANDS
STATE: TX
ZIP: 77381
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LEXICON PHARMACEUTICALS, INC./DE
CENTRAL INDEX KEY: 0001062822
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 760474169
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8800 TECHNOLOGY FOREST PLACE
CITY: THE WOODLANDS
STATE: TX
ZIP: 77381
BUSINESS PHONE: 2818633000
MAIL ADDRESS:
STREET 1: 8800 TECHNOLOGY FOREST PLACE
CITY: THE WOODLANDS
STATE: TX
ZIP: 77381
FORMER COMPANY:
FORMER CONFORMED NAME: LEXICON GENETICS INC/TX
DATE OF NAME CHANGE: 20000126
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2013-01-31
0001062822
LEXICON PHARMACEUTICALS, INC./DE
LXRX
0001434095
Tessmer James F
8800 TECHNOLOGY FOREST PLACE
THE WOODLANDS
TX
77381
1
VP, Finance & Accounting
Common Stock
2013-01-31
4
M
0
13200
A
41870
D
Common Stock
2013-01-31
4
F
0
4310
2.11
D
37560
D
Restricted Stock Units (Phantom Stock)
2013-01-31
4
M
0
13200
D
Common Stock
13200
0
D
Each restricted stock unit represents a contingent right to receive one share of common stock.
Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
Restricted stock units vest with respect to 100% of the shares subject to the restricted stock unit upon the dosing of the first patient in a pivotal human clinical trial in any country, the results of which could be used to establish safety and efficacy of a pharmaceutical product discovered or developed by the Company (whether or not licensed by the Company to a third party) as a basis for a New Drug Application with the U.S. Food and Drug Administration or that would otherwise satisfy the requirements of 21 CFR 321.21(c) or its foreign equivalent.
/s/ James F. Tessmer
2013-02-01